BG&A Builds Legal Case Against HHS Interference in Drug Pricing Negotiations

On February 24, Boyden Gray & Associates released an opinion letter explaining why the U.S. Department of Health and Human Service’s recent reinterpretation of Medicare Part D’s noninterference provision is unlawful and unsustainable. This letter was cited in the testimony of Douglas Holtz-Eakin, president of the American Action Forum, in a February 26 hearing before the House Energy & Commerce Committee.